Show Notes
Dr Jackson and Dr Barnes take a closer look at the hot topic of wearable devices in AF detection – their potential benefits and limitations – and how physicians can best discuss wearables with their patients.
More from Thrombosis in conversation
“Nobody ever said to me, ‘How are you doing?’ – which I think would have made a big difference.” Dr Barnes welcomes Leslie Lake, VTE survivor and volunteer president of the National Blood Clot Alliance, for a powerful conversation focused on the patient experience. Leslie shares her journey from a sudden pulmonary embolism and delayed diagnosis to living with the emotional impact of VTE. The discussion highlights the need for clinician awareness, the importance of ongoing risk assessment, and efforts to improve equity and access in blood clot care.
“I am sure 2026 is going to be even more exciting.” Dr Behnood Bikdeli joins Dr Barnes to discuss major advances in VTE and AF management in 2025, including the impact of trials such as API-CAT, RENOVE, and HI-PRO in VTE, and AMAFI, OPTION, and ADAPT-DES in AF. Highlights include the shift towards treatment personalisation and a “less is more” approach in clinical practice.
“Just being upfront with patients about those areas of uncertainty can be really helpful…” Dr Deborah Siegal and Dr Barnes break down best practices for balancing safety and efficacy when deciding how long to continue anticoagulation therapy for thrombosis. They discuss ways to reassure patients during an uncertain time, highlight key factors that modify bleeding risk, and explain how ongoing follow-up and reassessment are important in driving better outcomes.
“I think this was such an important trial, certainly one that has changed my practice already.” Dr Barnes welcomes Dr Marco Proietti for a review and discussion of key studies presented at ESC 2025, including AMALFI, ALONE-AF, and HI-PRO. Which results were practice-changing, which were reassuring, and which are of uncertain value or highlight a need for new therapeutics?
“We must be patient centred.” Dr Steven Deitelzweig and Dr Barnes address the challenge of balancing bleed risk and thrombosis prevention in special populations, such as those with obesity, frailty, or chronic kidney disease. With up to 50% of patients not resuming anticoagulation following a bleed, they emphasise the importance of shared decision-making to guide treatment in patients for whom the evidence is uncertain.